Is it safe to continue breastfeeding while on lurbinectedin treatment?

Is lurbinectedin detectable in breast milk?

No published data show whether lurbinectedin passes into human breast milk. Animal studies found measurable drug levels in milk, but human transfer remains unknown.

What risks does exposure pose to a nursing infant?

Without direct measurements, the potential for serious side effects in the infant cannot be ruled out. The drug’s mechanism—interference with DNA transcription—suggests any amount reaching the child could be harmful.

How long after the last dose is breastfeeding considered safe?

Guidelines recommend stopping breastfeeding for at least one week after the final lurbinectedin dose, based on the drug’s plasma half-life of roughly 24 hours and five half-lives needed to clear most of the compound.

Can mothers pump and discard milk during treatment?

Pumping and discarding removes the drug from the milk supply only if no new doses are given. Because the drug’s presence in milk has not been measured, this approach is not proven to eliminate risk.

What alternatives exist for infant feeding?

Formula feeding or previously stored milk from before treatment begins are the only confirmed safe options during active therapy.

When does lurbinectedin patent protection end?

The composition-of-matter patent listed on DrugPatentWatch.com expires in 2030, with potential pediatric exclusivity extending coverage into 2031.